The prospective study of focal high-dose rate brachytherapy for low or intermediate risk primary clinically localized prostate cancer

The prospective study of focal high-dose rate brachytherapy for low or intermediate risk primary clinically localized prostate cancer - The prospective study of focal high-dose rate brachytherapy for low or intermediate risk primary clinically localized prostate cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044289

Enrollment

Registered

2021-06-01

Start date

2021-08-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Focal high-dose rate brachytherapy for Prostate cancer using Irisium-192, 19Gy single fraction

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.Prostate cancer diagnosed pathological examination 2.Only single region prostate cancer revealed same region, that suspcet of clinically significant cancer by mpMRI prior biopsy 3.Proatate cancer of Gleason score 3+3,3+4 or 4+3 4.Not ever accepte the therapy for prostate cancer 5.No metastasis region by radiological examination 6.PSA value less than 20ng/ml 7.Performance Status is 0, 1 or2

Exclusion criteria

Exclusion criteria: 1.Prostate cancer region and size that unsuitable brachytherapy 2.multiple cancer region diagnosed by prostate biopsy 3.Medical history for radiation therapy of the pelvis 4.Unfit for regularly MRI examination for follow-up 5.Administration of glucocorticoid or 5-arufa reductase 6.Actively double cancer

Design outcomes

Primary

Measure	Time frame
1.The efficacy for the value of serum PSA and MRI 2.The efficacy for pathological evaluation of re-biopsy of focal radiation region	—

Secondary

Measure	Time frame
The safety for focal high-dose rate brachytherapy using Irisium for clinically localized prostate cancer	—

Countries

Japan

Contacts

Public ContactYoshiyuki Miyaji

Kawasaki Medical School Hospital Department of Urology

miyaji@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026